Genocea Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar '22 Mar 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Revenue	1.91	1.64	1.36	-	-	-
Revenue Growth (YoY)	40.62%	20.75%	-	-	-	-
Gross Profit	1.91	1.64	1.36	-	-	-
Selling, General & Admin	14.64	14.71	14.39	12.04	14.31	13.43
Research & Development	43.81	40.12	33.96	26.95	25.21	39.2
Operating Expenses	58.46	54.83	48.35	38.99	39.52	52.64
Operating Income	-56.54	-53.19	-46.99	-38.99	-39.52	-52.64
Interest Expense	-1.07	-1.12	-1.5	-1.6	-1.7	-1.7
Interest & Investment Income	-	-	0.12	0.65	0.68	0.26
Other Non Operating Income (Expenses)	19.33	20.02	4.66	0.99	12.73	-0.01
EBT Excluding Unusual Items	-38.29	-34.3	-43.71	-38.95	-27.81	-54.09
Merger & Restructuring Charges	-	-	-	-	-	-2.62
Other Unusual Items	1.1	1.1	-	-	-	-
Pretax Income	-37.19	-33.2	-43.71	-38.95	-27.81	-56.71
Net Income	-37.19	-33.2	-43.71	-38.95	-27.81	-56.71
Net Income to Common	-37.19	-33.2	-43.71	-38.95	-27.81	-56.71
Shares Outstanding (Basic)	70	69	44	21	10	4
Shares Outstanding (Diluted)	70	69	47	21	10	4
Shares Change (YoY)	29.43%	47.30%	125.50%	100.02%	188.67%	1.07%
EPS (Basic)	-0.53	-0.48	-0.98	-1.89	-2.69	-15.86
EPS (Diluted)	-0.53	-0.48	-1.11	-1.89	-2.69	-15.86
Free Cash Flow	-51.33	-48.66	-44.24	-38.87	-41.48	-48.78
Free Cash Flow Per Share	-0.73	-0.71	-0.95	-1.88	-4.02	-13.64
Gross Margin	100.00%	100.00%	100.00%	-	-	-
Operating Margin	-2958.87%	-3241.50%	-3457.62%	-	-	-
Profit Margin	-1946.15%	-2022.91%	-3216.63%	-	-	-
Free Cash Flow Margin	-2685.82%	-2965.14%	-3255.04%	-	-	-
EBITDA	-55.67	-52.34	-46.45	-38.29	-38.83	-51.41
D&A For EBITDA	0.88	0.86	0.54	0.7	0.69	1.23
EBIT	-56.54	-53.19	-46.99	-38.99	-39.52	-52.64

Updated May 5, 2022. Source: S&P Global Market Intelligence. Standard template. Financial Sources.